<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title><![CDATA[Aimmune Therapeutics, Inc. 보도자료 - 뉴스와이어]]></title><link>https://www.newswire.co.kr/?md=A10&amp;act=article&amp;no=39149></link><description><![CDATA[Aimmune Therapeutics, Inc. 보도자료 - 뉴스와이어 RSS 서비스]]></description><lastBuildDate>Fri, 01 May 2026 10:41:11 +0900</lastBuildDate><copyright>Copyright (c) 2004~2026 Korea Newswire All rights reserved</copyright><image><url><![CDATA[https://file.newswire.co.kr/data/upfile/company_img/2021/11/3554238800_20211115165059_1140043213.jpg]]></url></image><language>ko-KR</language><item><title><![CDATA[Aimmune Therapeutics Presents New PALFORZIA® [Peanut (Arachis hypogaea) Allergen Powder-dnfp] Data on Immunological Outcomes of Long-Term Daily Oral Immunotherapy at the EAACI PAAM Digital Meeting]]></title><link>https://www.newswire.co.kr/newsRead.php?no=934425</link><description><![CDATA[BRISBANE, Calif.--(Business Wire/Korea Newswire)--Aimmune Therapeutics, Inc., a Nestlé Health Science company developing and commercializing pharmaceutical therapies to prevent, manage, and treat food and metabolic-related diseases, today presented results from longitudinal analyses evaluating immunological outcomes of long-term daily oral immunotherapy (OIT) with PALFORZIA® [Peanut (Arachis hy...]]></description><pubDate>Mon, 15 Nov 2021 17:05:00 +0900</pubDate></item><item><title><![CDATA[에이뮨 테라퓨틱스, 유럽알레르기임상면역학회·소아알레르기천식학회서 새로운 ‘팔포지아 장기 일상 경구면역치료’ 데이터 공개]]></title><link>https://www.newswire.co.kr/newsRead.php?no=934426</link><description><![CDATA[브리즈번, 캘리포니아--(Business Wire/뉴스와이어)--식품 및 신진대사 관련 질병을 예방·관리·치료할 약물 요법을 개발·상업화하는 네슬레 헬스 사이언스(Nestlé Health Science)의 에이뮨 테라퓨틱스(Aimmune Therapeutics, Inc., 이하 에이뮨)가 땅콩 알레르기(PA) 환자를 대상으로 최대 6년간 매일 팔포지아(PALFORZIA®, 땅콩 알레르기 유발 항원 분말-dnfp)를 이용해 장기 경구 면역 치료(OIT)를 한 면역학적 결과를 검토...]]></description><pubDate>Mon, 15 Nov 2021 17:05:00 +0900</pubDate></item></channel></rss>